Have you ever wondered just exactly how your corn develops in the cob? Understanding how corn makes a cob, successful kernels, and packs in starch can be a key component of an agronomic plan.

This top part is the tassel, and that is the male part of the plant, says Sara Meidlinger, market development agronomist for Pride Seeds. Then we have the ear here, its going to develop silks, and its the female part of the plant.

In this episode of Corn School, Meidlinger gives us an overview of how pollination happens and what to expect during a corn crops reproductive stages.

The tassel will emerge and start to shed pollen, and kernels in the ears will shoot up a silk. Every kernel in a cob starts from a developing a silk, which is then fertilized by pollen from the tassel. A pollen tube develops, where the male genetics will travel down the silk towards the kernel. The whole process will take about seven to 10 days. Peak pollen shed from the tassel happens about three to four days after the process has started.

Meidlinger suggests pulling off some ears and getting familiar with your crop over the next couple of weeks. There are six stages that get that cob of corn to maturity:

If you happen to come across European corn borer or cutworm perhaps youve had corn heavy in the rotation it might be a good opportunity to switch to a different hybrid. While youre checking on your corns maturity, its a good time to scout for any insect issues, too.

Subscribe: Apple Podcasts | Android |

See the original post here:
Corn School: The birds and the bees of corn that, is - RealAgriculture

Recommendation and review posted by Bethany Smith

Corporate scientists have received final approval from the Environmental Protection Agency (EPA) to release hundreds of millions of genetically altered mosquitoes into the Florida Keys. The goal? To begin reining in the mosquito population, which is only expected to increase as climate change continues to warm and flood the low-lying, tropical Keys. But some environmental groups object strongly to the move.

Dive deeper. Read best-in-class science features and get unlimited access to Pop Mech, starting now.

Heres how the plan is designed to work: Local officials want to use these neobugs as an alternative to insecticides. The genetic modification, which is a common one being explored by scientists around the world, involves making female larvaeresponsible for laying eggsdie off very young before they can reproduce.

Male mosquitoes spread the gene, and in practice, this means any males spend their, uh, best years passing around a population-reducing time bomb. By generations, the population continues to dwindle.

But does this plan actually work?

While it's hard to find coverage of these events that arent from groups that lobby against genetically modified organisms, that doesnt necessarily mean these groups are wrong. In 2019, a controlled release in Brazil made news around the world when the genetically modified mosquitoes not only lived into fruitful adulthood, but began interbreeding and maybe even strengthening the local mosquito populations. That was a few years after a promising release killed 95 percent of problematic mosquitoes in a Brazilian trial.

This content is imported from {embed-name}. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

This has led to accusations that biotech firms that plan these events have taken the wrong lesson, to say the very least, from genetic engineering cautionary tales like Jurassic Park. Scientists continue to research ways to self-limit insects using genes, like invasive moths that destroy crops and are resistant to existing chemical technology. With mosquitoes, the stakes are even higher because of the diseases they carry.

Discussing evolution and genetics can end up assigning agency in a strange wayas though an animal chooses something to become, or that the environment chooses which organisms will survive. Whats interesting about breeding self-limiting pests is that a naturally occurring organisms with a gene like this would rapidly die out. Theres no way to breed a natural population the way you might breed flowers of a certain color or a new designer cat breed.

Sponsoring organization Oxitec has focused on the positives of a project like this, and indeed, mosquitoes are gigantic pests that cause almost unfathomable disease spread around the world. Theyre such a bane that people freely suggest wiping them all the way out, which isnt the panacea it sounds like due to, again, those pesky unforeseen environmental consequences.

The Oxitec experiment has gone through layers of approval, from local all the way up to the EPA. Oxitec must notify state officials 72 hours before releasing the mosquitoes and conduct ongoing tests for at least 10 weeks to ensure none of the female mosquitoes reach adulthood, CNN reports.

Please also let us know if anyone sneaks in or out with a suspicious Barbisol can.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

The rest is here:
Release 750 Million Genetically Modified Mosquitoes Into the Wild, They Said - Popular Mechanics

Recommendation and review posted by Bethany Smith

750 million genetically-modified mosquitos will be released in Florida, as a project to use the mutant bugs to try to control dengue fever, Zika, and other diseases gets the green light. The controversial Oxitec project was granted EPA approval earlier this year, but it was only this week that local regulators gave the go-ahead to the trial.

At the heart of it is a specially customized mosquito. All male, and non-biting, its designed to breed with wild female mosquitoes of the invasive Aedes aegypti species. Its this type which has been found to transmit diseases like dengue, yellow fever, Zika, and chikungunya.

Problem is, theyre also increasingly resistant to pesticides, and that growing tolerance has made chemical attempts to kill the mosquitos off less effective over time. As a result, the Florida Keys Mosquito Control District (FKMCD) has been working with Oxitec on the genetically modified bugs instead.

The idea is straightforward. The male, modified mosquitoes mate with the wild female ones, but also carry a protein thats designed to kill female offspring before they reach the stage where they too would begin biting. Male offspring, however, will survive, but carry on the tweaked genetics to further expand the trial.

The FKMCD board voted four to one in favor of the trial, following Federal and State approvals of an Experimental Use Permit issued by the EPA in May 2020. Part of the requirements set out by the EPA limit where the modified mosquitoes can be released, including not permitting them near to circus orchards, and reporting any adult female mosquitoes found to have reached that age with the OX5034 generic construct.

Its not been a smooth path to this point, however. Environmentalists have pushed back against Oxitecs plans, accusing the company of testing unproven science in public, and raising concerns that the midst of a pandemic is not the right time for it. There are also worries among some that unforeseen mutations could lead to even more resistant versions of the bugs.

Contesting those fears, Oxitec points to similar demonstration projects that took place in Brazil. There, the modified mosquitoes reportedly suppressed disease-carrying Aedes aegypti mosquitoes by up to 95-percent in a high 2-week rolling average after 13 weeks, compared to untreated control sites in the same city.

Exactly when the Florida release will go ahead has not been settled upon. The exact time and location of the trial has yet to be determined, the FKMCD says, but the current Experimental Use Permit granted to Oxitec dictates trials must be completed by 2022. Both the FKMCD and Oxitec have previously said that they plan sometime in 2021 for the launch.

View post:
Mutant mosquitoes approved to help Florida fight dengue and Zika - SlashGear

Recommendation and review posted by Bethany Smith

Autoplay

Show Thumbnails

Show Captions

With many parents still working from home in the midst of a global pandemic as students return to the virtual classroom, some may wonder if the shows theirkids are streaming when they're not in class are doing anything to stimulate their minds.

Or are they just distracting the kids enough for you to get your work done when they could be doing both?

The good news is, there are plenty of options now available on streaming services to sneak some education into any student's viewing diet while for all they know they're merely being entertained.Choices include shows such as "Avatar: The Last Airbender," "Connected: The Hidden Science of Everything,"or"The World According to Jeff Goldblum."

Keep in mind not everything on this list will be appropriate for every child.

This educational comedy series features comedian Adam Conover debunking common misconceptions by using his magical TV host powers but also by referencing peer-reviewed articles and reaching out to experts in the field.

Each episode ends with a positive takeaway explaining how the knowledge you've just gained is better for you than the comfort of the misconceptions he's just ruined.

The Wall Street Journal said of Conover, "In short, he's irritating. But he owns it. Which makes his quasi-educational comedy series so goofily endearing."

Fast Company called him "the lovechild of Debbie Downer and the coolest, most contrarian college professor you ever had."

All three seasons of "Avatar: The Last Airbender" premiered on Netflix on May 15. Since the world is still in quarantine, now is a great time to watch it yourself for the first time or binge the series for the 50th time.(Photo: Courtesy of Forbes)

This animated series portrays the adventures of 12-year-old Aang, the last surviving Airbender, who awakens from a century in suspended animation to find the world at war.

As the spirit of light and peace in human form, Aang controls the elements and is tasked with keeping the Four Nations at peace.

Critics praised the series for addressing concepts rarely touched on in entertainment aimed at young kids, from war to genocide, imperialism, colonialism, totalitarianism and free choice.

It has a critics score of 100 on Rotten Tomatoes. Vanity Fair named it one of the best animated series since "The Simpsons," noting that it "teaches without tryingand is a shining example of what it means to show unconditional devotion to a greater cause."

This Pixar animated feature wasinspired by Da de los Muertos.

It tells the story of 12-year-old Miguel, who's magically transported to the Land of the Dead, where he enlists his deceased great-great-grandfather to help him return to the land of the living and reverse his family's ban on music.

Rolling Stone's Peter Travers praised this "loving tribute to Mexican culture," saying "Of course, a lesson is being preached to children about the need to respect elders. But Pixars 19th feature brings a soulful core to that message."

The Wrap said, "If an animated movie is going to offer children a way to process death, it's hard to envision a more spirited, touching and breezily entertaining example than Coco."

It was named best animated film of 2017 by the National Board of Review, the Golden Globes and the Critic's Choice Movie Awards.

Latif Nasser in Netflix's "Connected."(Photo: Netflix)

Here's a fun way to sneak in some science.

Latif Nasser, director of research at an award-winning New York Public Radio show called "Radiolab," investigates the surprising and intricate ways in which we're all connected to each other, the world and the universe in this six-part 2020 docuseries.

There are episodes on how surveillance pervades our lives, the power of dust, important lessons of nuclear bombs and a law of numerical probability that applies to classical music, contemporary social media, tax fraud and perhaps the universe at large.

It helps to have a host with the nerdy charisma Nasser brings to the proceedings. As Decider wrote, "This is a man who can turn weave a jaw-dropping story out of probability."

What were the odds?

CrashCourse is an educational YouTube channel started by John and Hank Green and funded by YouTube's $100 million original channel initiative.

Since launching a preview in late 2011, the channel has earned more than 10 million subscribers and 1 billion views.

At first, the channel focused on humanities and science courses, having launched with episodes on world history and biology. But after partnering in later 2014 with PBS Digital Studios, the brothers were able to expand the curriculum, recruiting additional hosts.

A second channel, Crash Course Kids, is hosted by Sabrina Cruz and has completed its first series, Science.

A collaboration with Arizona State University titled Study Hall began in 2020, offering less structured learning.

This Netflix docu-series has been around longer than "History 101" but follows a similar format.

Each episode is devoted to a single mini-lesson lasting less than 20 minutes.

Among the more serious topics the series has explored are the racial wealth gap, designer DNA, monogamy, political correctness, why women are paid less and the world's water critics. But other episodes have ranged from K-pop to cricket.

The show has had some interesting guest narrators, from Christian Slater talking cryptocurrency to John Waters on beauty, Kristin Bell on whether we can live forever (spoiler alert: we can't) and Carly Rae Jepsen on music.

"Explained" has spawned three spin-off miniseries: "The Mind, Explained," "Sex, Explained" and "Coronavirus, Explained."

Cynthia Erivo plays Harriet Tubman in "Harriet."(Photo: Glen Wilson)

Born into slavery, famed abolitionist Harriet Tubman escaped to Philadelphia in 1849, returning to the South rescue family members and eventually a total of approximately 70 enslaved people via the Underground Railroad, a network of safe houses.

Cynthia Erivo, who stars as Tubman, brought home acting nominations from the Academy Awards, Golden Globes and the Screen Actors Guild.

How accurate is it? Fairly.

A story in Slate says the filmmakers "take some considerable liberties with both the timeline of events and the creation of several characters."

And director Kasi Lemmons told USA Today the film's creators took creative liberties in fleshing out the character of her slave owners vengeful grandson, Gideon.

Now streaming on several HBO platforms.

This Netflix documentary series definitely makes good on the Intro to History implications of its title. Each episode is ahistory mini-lessonconsisting of archival footage, facts and graphs about various topics.

Since the series premiered in May, those mini-lessons have included episodes on fast food, the space race, the rise of China, plastics, oil and the Middle East, robots, feminism, nuclear power and genetics.

A review of the series at Ready Steady Cut! concluded "History 101" season 1 is worth a binge it wont take long and you may learn something new."

Jamie Hyneman (left) and Adam Savage, hosts of the Discovery Channel show 'MythBusters.'(Photo: Handout courtesy of Discovery Channel)

This show is a blast quite often literally.

In its first nine seasons, 12 tons of explosives were used as special effects experts Adam Savage and Jamie Hyneman employed the scientific method to test the validity of urban legends, rumors, myths, adages, movie scenes, videos and news.

The duo used a two-step method of replicating the circumstances tosee if they could duplicate the alleged results. By the end of each episode, the myths were rated busted,plausibleor confirmed.

The series premiered in 2003 on the Discovery Channel and ran through 2016 before being revived in 2017 with new hosts on the Science Channel. The original series is streaming now on Hulu.

The human body is the focus of this British children's television series, hosted by twin brothers Dr. Chris and Dr. Xand van Tulleken, who were joined in 2019 by a third host, Dr. Ronx.

In the interest of demystifying what happens in hospitals for younger viewers while explaining how our bodies work, the doctors undergo experiments on their own bodies.

Those experiments have ranged from scrambling their own brain signals to show how they control body movements to charting what happens to food in the digestive tract with a special camera pill.

So yes, it has been known to get a little gross. You'll find out the medical uses of maggots, for instance.

Each episode also follows children admitted to hospitalwards from diagnosis to recovery.

Marie Curie (Rosamund Pike) at work in the lab in a scene from 'Radioactive.'(Photo: Laurie Sparham)

"Radioactive" tells the inspiring tale of Marie Curie and the pioneering work she did that resulted in Curie becoming the first woman to be honored with a Nobel Prize.

Filmed in Hungary with great costuming and a brilliant performance from Rosamund Pike in the title role, it touches on the discrimination she faced as a Polish woman in Paris as well as her struggles to be heard in the male-dominated scientific community.

Scientific American said it portrayed Curie as "a woman of the future."

However, somehave criticized the film for taking far too much creative license with the truth, inspiring STEM on Stage to compile a list of historic inaccuracies.

Parents should also know that it contains brief nudity.

Streaming now on Prime Video.

This PBS series is hosted by a physicist named Dr. Derek Muller, who spends each episode unlocking the mysteries as well as explaining the history and uses of uranium, one of Earth's most controversial elements.

In Part 1: The Rock That Became a Bomb, Muller explores how uranium becomes lead in the process of radioactive decay, the harmful effects of radiation and the use of uranium as a nuclear weapon.

The episode ends with the bombing of Hiroshima at the end of World War II.

In Part 2: The Rock That Changed the World, he looks at the use of uranium in cancer treatment and visits Chernobyl and Fukushima, where nuclear disasters have occurred.

Did you know that dinosaurs didn't roar? Or that astronauts shrink in space? I can almost guarantee you didn't know that in 16th Century England, it was considered good luck to throw shoes at the bride and groom at weddings? THAT'S who throws a shoe.

Whether hunting for dinosaur fossils or flying planes, the science-loving Engelman siblings that host this National Geographic Kids series explore the weird but true science that makes this world or in the case of shrinking astronauts, this universe a fascinating place.

This show is clearly aimed at younger kids, who should respond well to the goofy children's-entertainer energy the Engelmans invest in making learning fun and often funny (if admittedly seven miles over-the-top for viewers past a certain age).

Jeff Goldblum: Oct. 22, 1952.(Photo: Monica Schipper/Getty Images)

The premise of this series is as quirky as the host himself.

He prepares for an episode by doing as little research as humanly possible on the topic at hand, from ice cream to RVs, relying instead on his ownunderstanding of the topicjust from living in this world.

But there's a method to this seeming madness, as the actor explained at a panel reported by IGN,

"I kind of encounter interesting people around these subjects and you see me, you go along with me, if you're so inclined, and we have this experience together," he said. "That's the idea. Its all a surprise to me. I don't even meet the people, see the places, before they turn on the camera. Its all me kind of like a chick popping out of its shell."

Reach the reporter at ed.masley@arizonarepublic.com or 602-444-4495. Follow him on Twitter @EdMasley.

Support local journalism.Subscribe to azcentral.com today.

Read or Share this story: https://www.azcentral.com/story/entertainment/kids/2020/08/21/want-streaming-options-also-educational-try-these-programs/3367640001/

Read the original:
Try these streaming options to add some educational viewing to your kids screen time - AZCentral

Recommendation and review posted by Bethany Smith

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
Induced Pluripotent Stem Cells Market Size Is Anticipated To Reach US$ 17200 Mn at a CAGR of 7% By 2026, Owing to Increasing Number of Product...

Recommendation and review posted by Bethany Smith

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Stem Cell Therapy Market Segmentation, Assessment and Growth Opportunities by Forecast 2025 - Scientect

Recommendation and review posted by Bethany Smith

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and othersPublic awareness associated to the therapeutic prospective of stem cellsGrowing number of hematopoietic stem cell transplantations (HSCTs)Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the marketIntense competition among the stem cell companiesSometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem CellBanking MarketIndustry Trends and Forecast to 2026

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform.In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market.Learn about the market policies that are being endorsed by ruling respective organizations.To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape.To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments.Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries).To strategically profile the key players and comprehensively analyze their growth strategiesTo analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country levelAll products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ [emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Read the original post:
Global stem cell banking market Enhancement And Its growth prospects forecast 2020 to 2027 - Scientect

Recommendation and review posted by Bethany Smith

On April 15, 2002, the FDA approved a temporary treatment for wrinkles that would revolutionize aging. All of a sudden, you could waltz into a derms office and get your frown lines ironed out faster than it would take to iron an actual shirt. It was called botulinum toxin,Botox for short.

Eighteen years later, a few units of Botox every three months has become the norm for millions around the world (more than seven million yearly in the U.S. alone). Now, if someone had told your grandparents, or even your parents, 20 years ago that people would be getting their foreheads frozen to look younger, they likely would have scoffed at the idea. So just imagine what other wild fixes could be coming to a medi-spa near you.

Its exciting to think about how the next 10 years will look, says Dr. Rohan Bissoondath, medical director of Calgarys Preventous Cosmetic Medicine clinic. With lifespan increasing, people are routinely going to be living into their hundreds, so we want to look great as well. From magic pills to creams that mimic injections, we take a look at the incredible innovations on the horizon.

The best products worth your time, money and energy get beauty news and more delivered to your inbox with our daily newsletter.

The way science is progressing, facelifts are set to become obsolete, says Dr. Lisa Kellett of Torontos DLK on Avenue. I think that the gold standard will eventually be finding ways to regenerate and kick-start our own collagen instead of doing a facelift. Kellett is already trying out cutting-edge technology to accomplish this, such as a laser that delivers growth factors right in the dermis to regenerate tissue. Its pretty snazzy stuff, but she anticipates even greater advances in coming years. I think well be able to use stem cells in conjunction with technology to regenerate collagenI think thats what well be doing one day.

Botox in a cream? This has been in the pipeline for a while, says Bissoondath. The challenge is getting the molecules to penetrate the skin so that they can act on the muscle. Maybe on crows feet because its a thinner area, thinner muscles; that may be an area where we see some utility for it, but its still out there. Topical Botox had some success in trials, but scientists still have kinks to work out. In the meantime, a Botox cream might be beneficial even if it doesnt reach muscles, says Bissoondath. I see the potential for having it in a cream and applying it to the whole face, not necessarily affecting facial expressions, but giving an improved glow and better skin quality.

If you want to smooth, you get Botox. If you want to brighten, you get IPL. If you want to tighten, you get Thermage. But what if there was a treatment that did it all? I think thats the future of aging, says Kellett, who is just about to launch such a treatment at her clinic. Marketed as the next generation of laser and light-based platform technology, Ethera is a multiple modality device that can tackle everything from dark spots and skin laxity to textural issues and wrinkles. It means that when patients come in, theyre not just doing one thing, says the doc. Instead, in the same appointment, shes able to address a variety of concerns with a single machine.

Okay, this is very cool. Something I think is possible is a pill to replace exercise, says Bissoondath, who adds that this could be developed in the not so distant future. With the advances were making in understanding the functions of our body down to the cellular level and intracellular level, and understanding how our mitochondria actually ages, were looking at ways now where we can manipulate that from a pill perspective. The pill wouldnt deliver all the benefits of physical activity, such as the positive impact on our mood, but it would replicate its effects on our body. It wont take the place of walking around outside and soaking up natureit cant do the mental part of it. But as far as the physiologic, biochemical part of it, were really understanding that better and making big strides. Its exciting.

Read more here:
Best Anti Aging Advances to ComeHow We'll Soon Be Looking Younger - The Kit

Recommendation and review posted by Bethany Smith

VAIL, Colorado, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health (NIH). SPRI Chief Scientific Officer Johnny Huard, Ph.D. will serve as the principal investigator. Marc J. Philippon, M.D., who serves as managing partner of The Steadman Clinic and co-chair of SPRI and Scott Tashman, Ph.D., director of biomedical engineering at SPRI, will serve as co-principal investigators. The clinical trials are expected to begin enrolling in the Fall of 2020.

The award, administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, ranks as one of the most significant in SPRIs history, both in size and recognition. Given the potential of regenerative medicine to enhance human health and treat disease, the United States Congress included a provision in the 21st Century Cures Act a law passed in December 2016 to accelerate medical discovery and innovation to support the NIH-established Regenerative Medicine Innovation Project (RMIP). The RMIP aims to accelerate the field by supporting clinical research on adult stem cells while promoting the highest standards for protecting patient safety during the conduct of research.

This is a really great honor for SPRI, said Dr. Huard, who first came to Vail in 2015 and has served as the director of the Center for Regenerative Sports Medicine in addition to his role as the institutes chief scientific officer. Past recipients of these RMIP awards have been Albert Einstein College of Medicine, Boston Childrens Hospital, Columbia University Health Sciences, Childrens Hospital of Philadelphia, Harvard University, University of Colorado Denver and Yale University.So, we are in very good company.

The grant anticipates over $2.8 million from the NIH and requires a 1:1 match from SPRI over the next five years, pending availability of federal funds. The clinical trials and resulting publications and reports will take place over the next five years. A generous SPRI benefactor committed to fund the first year of the match, and Dr. Huard is hopeful that with the NIH matching the funds, more philanthropists will be inspired to become involved in this groundbreaking project.

Our donors have been so generous in supporting all that we do here at SPRI, said Dr. Huard, and I am very grateful and confident that we will raise the funds necessary to complete these trials over the next five years.

The trial is entitled,The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis. Huard explains in laypersons terms:

The idea behind the trial is to delay osteoarthritis in the knee, said Huard. Our goal is to delay the need for that first knee replacement in a patient for as long as we can. Over time SPRI intends to expand this area of research to other joints including hip and shoulder.

This clinical trial is designed to determine whether senolytic and/or antifibrotic agents will improve the beneficial effect of Bone Marrow Stem Cells for the treatment of symptomatic knee osteoarthritis. The trial will include four groups, totaling 100 patients, to investigate the teams hypothesis that the use of these agents will improve patient outcomes.

One of the great things that I love about this particular clinical trial is that we are actively involving our orthopaedic surgeons and our biomotion lab staff as well, said Dr. Huard. This will truly be a team effort over the next five years.

Those world-class surgeons are led by Dr. Philippon, considered one of the worlds foremost orthopaedic surgeons. The biomotion lab is under the direction of Dr. Tashman. The contributions of these two leaders and the talented roster of surgeons, clinicians and technicians in their departments will be critical to the success of the upcoming clinical trials. SPRIs Center for Outcomes-Based Orthopaedic Research and its director Grant Dornan are also participating in this project by contributing the statistical outcomes.

Dr. Philippon is not only a world-class surgeon but he is also an innovator, added Dr. Huard. He always wants to improve and is still willing to try new things to enhance patient outcomes. Dr. Tashman is the same way. Like everyone here at SPRI and The Steadman Clinic, they are embracing the cutting-edge technology available to them and finding new and better ways to treat patients and, most importantly, reduce patients recovery time and get them back to their active lives as quickly and safely as possible.

Huard notes that the rare combination of a globally recognized research institute like SPRI and a world-class orthopaedic surgery clinic like The Steadman Clinic in the same building is one of the key factors in the awarding of this RMIP grant.

Weve got something here in Vail that many other research institutes dont have, said Huard. We have one of the worlds finest orthopaedic clinics right next door, working hand-in-hand with us every day.

Dr. Huard and Dr. Tashman along with Suzanne Liv Page, J.D., our director of grants and contracts have worked diligently to prepare and gain acceptance of this grant proposal from the NIH, said Dr. Philippon. Our surgeons here at The Steadman Clinic eagerly await the opportunity to participate in the trial. Johnny, Scott and their staff have put SPRI into position to undertake major trials and studies like this one and we are all very honored that the NIH has given SPRI this incredible opportunity.

For further information or other inquiries about The Steadman Clinic or Steadman Philippon Research Institute, contact Lynda Sampson, Vice President of External Affairs (lsampson@sprivail.org).

Link to current SPRI clinical trials - https://www.sprivail.org/about-us/clinical-trials

Read more:
Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health - GlobeNewswire

Recommendation and review posted by Bethany Smith

Global Skin Packaging Market industry is anticipated to an extensive growth during the forecast period 2018-2023. Skin Packaging Market report provides in detail analysis of market with revenue growth and upcoming trends. report contains the forecasts, market size, share estimates and profiles of the leading industry Players.

Skin Packaging Market research report provides derived key statistics, based on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Skin Packaging industry. The report is a reliable analysis of current scenario of the market, which covers several market dynamics.

Get a Sample Copy Of The Report At https://www.absolutereports.com/enquiry/request-sample/13101691

The global skin packaging market is estimated to be worth USD 8.08 billion in 2018, and is projected to reach USD 11.05 billion by 2023, at a CAGR of 5.36% during the forecast period (2018 2023). The scope of the report is limited to type of end-user vertical, such as fast-moving consumer goods, and retail, among others. The regions considered in the scope of the report include North America, Europe, Asia-Pacific, and Rest of the World.

Skin packaging is a process where heated film is draped over a product, and a vacuum is utilized to draw the film down onto the package, creating a secure and attractive package. It is a low-cost packaging option, and is used to protect the products during shipments, and display the products. Packaging, in smaller volume, is the trend that is observed lately. Increasing the shelf life has been the major goal of packaging companies, and therefore fresh products are increasingly packaged in skin films. The modern lifestyle of consumers has been forcing them to try to save time and money, which resulted in increasing demand for ready-to-eat products. This trend has encouraged the packaging companies to come up with diverse options for consumers, thereby driving the sales of packaging applications lucratively.

Asia-Pacific to Dominate the Food Industry

The food market in Asia-Pacific region was estimated to be USD 885.2 billion in 2016 and is projected to reach USD 1,216.5 billion by 2021, registering a CAGR of 6.6%. The sub-sectors that are expected to use skin packaging the most include- meat products & sausages, processed fish & seafood, and processed vegetables & fruits.

Packaging is globally accepted as a significant parameter for brand owners to market their products at stores and on e-commerce platforms. The meat counters in stores have always been a very traditional and staid part, which offers minimal opportunity to differentiate the brand. Captivating consumers attention has been one of the reasons for adopting skin packaging, among others. The secondary sealing of vacuum skin packaging is visually appealing for seafood and meat packagers. They also help to minimize the migration of liquids inside the packaging, for an appetizing and appealing presentation of the package.

Downsizing of Packaging to Drive the Growth of Skin Packaging Market

Due to globalization, increasing middle-class population, and changing lifestyles of people, there has been a huge demand in the packaging market. In the recent times, there has been a rising demand for miniaturization of packaging, due to the ready-to-eat convenience for customers. Due to an increase in the cost of raw materials, the size of food packaging has been shrinking. In every economic downturn, companies have been either reducing the size of the products or increasing the price of same-sized products. Consumers have become increasingly aware of the significance of recycling. Skin packaging, which is basically a combination of cardboard and plastic, can be separated after use. Smaller packages being environment-friendly, portable, and healthy, are preferred over bigger packages. As consumers are more sensitive to change in prices than that of quantity, companies opt for reducing the size of packages. Due to this extreme downsizing of packages, the skin packaging market (both vacuum and thermoforming) has undergone a fast-paced transformation.

Key Developments in the Market

August 2017 Sealed Air Corporation introduced OptiDure packaging technology combining two critical features: high-abuse resistance and abrasion protection, and will impact the fresh red meat, as well as smoked and processed meat segments February 2017 Lintop launched LINTOP SKIN FILM range to enhance the performance and shelf-appeal of products. February 2017 Clondalkin Flexible Packaging (CFP) launched an innovative stand up pouch with extended shelf life properties

Major Players: SEALED AIR CORPORATION, BERRY PLASTICS GROUP INC., BEMIS COMPANY INC., and WEST ROCK COMPANY, amongst others.

Major Regions: Argentina, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Rest of Asia-Pacific, Rest of Europe, Rest of Middle East & Africa, Rest of North America, Rest of South America, Saudi Arabia, South Africa, South Korea, Spain, UK, US

Inquire Or Share Your Questions If Any Before The Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/13101691

Reasons to Purchase this Report:

Major Points Covered in Table of Content of Skin Packaging Market forecast 2023

1. Introduction of Skin Packaging Market Report

1.1 Study Deliverables

1.2 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3. Executive Summary

4. Market Overview and Skin Packaging Market Trends

4.1 Introduction

4.2 Market Trends

4.3 Porters Five Force Framework

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Consumers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry within the Industry

5. Skin Packaging Market Dynamics

5.1 Drivers

5.2 Restraints

5.3 Opportunities

6. Global Skin Packaging Market, Segmented by Size

7. Global Skin Packaging Market, Segmented by Technology Type

Purchase This Report (Price 4250 USD for single user license) https://www.absolutereports.com/purchase/13101691

8. Global Skin Packaging Market, Segmented by Geography

8.1 North America

8.1.1 United States

8.1.2 Canada

8.1.3 Mexico

8.1.4 Others

8.2 South America

8.2.1 Brazil

8.2.2 Argentina

8.2.3 Others

8.3 Asia-Pacific

8.3.1 China

8.3.2 Japan

8.3.3 India

8.3.4 Others

8.4 Europe

8.4.1 United Kingdom

8.4.2 Germany

8.4.3 France

8.4.4 Others

8.5 Africa and Middle East

8.5.1 UAE

8.5.2 South Africa

8.5.3 Saudi Arabia

8.5.4 Others

9. Competitive Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Developments of Key Players

10. Key Vendor Analysis (Overview, Products & Services, Strategies)

11. Future Outlook of the Market

12. Disclaimer

And Many More.

For Detail TOC Click Here

About Absolute Reports:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Absolute Reports

Phone: +14242530807/+44203239 8187

Our Other report :Global Bronze Rods Market 2020 Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026

Global Truck Engines Market 2020 Segmented by Application and Geography Trends, Growth and Forecasts to 2026

Global Aluminum Chloride Market 2020 Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026

Global Roof Truss Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2026

Global Silicate Based Coatings Market 2020 Key Players, Industry Overview, Supply Chain and Analysis to 2026

Tunneling Machinery Market 2020: Size, Share, Growth, Sales and Drivers Analysis Research Report 2025

Global Biaxially Oriented Polypropylene (BOPP) Market 2020 Key Players, Industry Overview, Supply Chain and Analysis to 2024

Stem Cells Market 2020 Research Analysis by Product Overview and Scope and Suppression Systems Forecasts 2024

Global K-Feldspar Powder Market2020Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2026

PETE Market Outlook 2026: Market Trends, Segmentation, Market Growth and Competitive Landscape

Global Laminate Flooring Market 2020 Growth Factors, Types and Application by Regional Geography 2024

Quantum Cascade Laser Market Analysis, Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2025

Plum Wine Market Size 2020 Industry, Trends, Global Growth, Insights and Forecast Research Report 2026

Global N-Bromosuccinimide Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2024

Anaerobic Sealants Market Size 2020 Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2026 Research Report

Global Melanoma Scanner Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and Production Value

See the rest here:
Global Skin Packaging Market Share, Growth, Trend Analysis and Forecast from 2020-2023; Consumption Capacity by Volume and Production Value - Bulletin...

Recommendation and review posted by Bethany Smith

This Exosome Therapeutic Market report comprises of the most recent market information with which companies can have in depth analysis of industry and future trends. By identifying the marketing strategies of rivals, businesses can set up innovative ideas and striking sales targets which ultimately make them achieve competitive advantage over its competitors. Because businesses can achieve great benefits with the different segments covered in the business document, every bit of market that can be included here is touched carefully. This report provides statistics on the current state of the industry as a helpful source of assistance and direction for companies and investors interested in this market.

This is the most relevant, unique, and creditable global business document which has been brought to valuable customers and clients depending upon their specific business needs. The Exosome Therapeutic Marketreport also displays important product developments and tracks recent acquisitions, mergers and research in the industry by the major players. Moreover, all the stats, data, facts and figures collected to prepare this market report are obtained from the trustworthy sources such as websites, journals, merges, newspapers and other authentic sources. Exosome Therapeutic Marketanalysis report also includes CAGR value fluctuations with respect to rise or fall for the certain forecast period.

Exosome therapeutic marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

Pipeline analysis

PART 06: MARKET SIZING

Market definition Market sizing Market size and forecast

PART 07: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 08: MARKET SEGMENTATION

Segmentation Comparison Market opportunity

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison North America South America Europe MEA APAC Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

Market drivers Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

Overview Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

PART 16: APPENDIX

List of abbreviations

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Research objectives

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

More here:
Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United...

Recommendation and review posted by Bethany Smith

Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.

Get Sample PDF of Report @https://www.premiummarketinsights.com/sample/AMR00026846

Key Players:

Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co., Inc. (FloDesign Sonics),NantWorks, LLC,Neurogeneration, Inc.,Novartis AG,Plasticell Ltd.,Regeneus Ltd,StemGenex, Inc.

Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market.

Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, rise in adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.

The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

Avail Discount on this[emailprotected]: https://www.premiummarketinsights.com/discount/AMR00026846

KEY MARKET SEGMENTS

By Offering Type Products Services Software

By Application Cardiovascular Devices Bone Repair Neurological Disorders Skeletal Muscle Repair Cancer Others

By Region

North Americao U.S.o Canadao Mexico Europeo Germanyo Franceo UK

Key question and answered in the report include:

About Premium market insights:

Premiummarketinsights.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Sameer Joshi Call: US: +1-646-491-9876, Apac: +912067274191Email:[emailprotected]

Follow this link:
Cell Therapy Processing Market is Booming Worldwide to Show Significant Growth by 2026 Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co.,...

Recommendation and review posted by Bethany Smith

OneAZ Credit Union names Ken Bauer SVP

OneAZ Credit Union announced Ken Bauer as senior vice president, Credit Administration.

Bauer oversees OneAZs mortgage, business and commercial banking teams, emphasizing efficiency and excellence to help the organization succeed. He joined OneAZ Credit Union in 2020, bringing 20 years of experience in commercial banking with local and national banks and credit unions.

Established in 1951, OneAZ Credit Union is owned by its members and serves Arizona with 20 locations and more than 140,000 members

Spencer Fane LLP announced Kelly Mooney has joined the firm as of counsel. She will be part of the Tax, Trusts, & Estates practice group and work out of the firms Phoenix office.

Mooneys practice focuses on handling complex matters related to federal taxation, working with attorneys in other practice groups to structure transactions that comply with federal tax law, offer tax relief when applicable, and provide tax-efficient results for her clients. She regularly assists clients with tax planning and analysis for partnerships, LLCs, and corporations; real estate joint ventures organized as LLCs and general and limited partnerships; and individuals.

Spencer Fane understands that tax issues impact virtually every aspect of business, investment, and personal wealth management, said Andy Federhar, Spencer Fane office managing partner in Phoenix. We understand our clients needs to assist them with finding the best solutions to favorably handle their tax liability, and Kellys experience in handling these matters through collaborative analysis fits well with our firms approach to client service.

Mooney has an accomplished track record of representing clients before the Internal Revenue Service and other taxing authorities on ruling requests, civil controversy cases, and collection matters. Her work has included successfully negotiating the settlement of several complex and multiyear IRS examinations and cases involving the imposition of trust fund penalties and contested claims for refund.

The University of Arizona College of Nursing has announced key new appointments, promotions, honors, awards and other notable items in recent weeks, including:

After a national search, the UArizona College of Nursing has named Kelley Wilson, DNP, MSN, CMSRN, as the new program director of the colleges Master of Science for Entry to the Profession of Nursing (MEPN) program. Dr. Wilson joins the college from Georgetown Universitys School of Nursing and Health Studies, where she had been serving as program director for the schools Bachelor of Science in Nursing program. She assumed her new role on July 13.

Dr. Wilson brings a wealth of experience in teaching and developing courses and academic programs, said Connie Miller, DNP, RNC-OB, CNE, clinical associate professor and chair, General Nursing and Health Education Division. She has solid experience in mentoring and leading teams, in addition to proven track record of service and scholarship. We look forward to welcoming her to our MEPN team.

Aleeca Bell, PhD, RN, CNM, joined the College of Nursing in mid-July. Dr. Bell most recently was an associate professor at the University of Illinois at Chicago (UIC), College of Nursing, Department of Women Children and Family Health Science. At UIC, she also earned her masters degree in nursing in midwifery in 1998, practiced as a certified nurse midwife, and earned a doctorate in nursing in 2009. In addition, she was a postdoctoral fellow there from 2009-11.

Dr. Bells research in translational, multidisciplinary and biobehavioral clinical studies focuses on the intersection of perinatal mother-infant health outcomes and the underlying oxytocin system. Oxytocin is a hormone that acts on organs in womens bodies and as a chemical messenger in the brain, controlling key aspects of the reproductive system, including childbirth, lactation and some behavior. This includes womens childbirth experience, intrapartum medical interventions, the endogenous oxytocin system (hormonal, genetic and epigenetic), maternal postnatal mood/anxiety and caregiving attitudes, newborn behaviors and mother-infant interaction. Learn more.

Tracy E. Crane, PhD, a College of Nursing assistant professor, has focused much of her career on cancer survivorship. She is co-director of the Behavioral Measurements and Interventions Shared Resource at the UArizona Cancer Center and a member of the UArizona Data Science Institute. Shes also co-chair of the cancer prevention and control behavioral science working group for NRG Oncology, a research non-profit led by faculty at Columbia University, NYU Langone Health, the University of Michigan and UArizona.

With a research focus on improving adherence to healthy lifestyle behaviors in cancer survivors and their informal caregivers, Dr. Crane has developed interventions geared toward extending lifespans of post-treatment ovarian cancer survivors and telephone counseling to improve diet and physical activity in Latina cancer patients. In early 2020, Dr. Crane extended her expertise across the Atlantic when she helped researchers at Gustave Roussy, Europes largest cancer center, fine-tune a new cancer study, Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer (MEDEA).

In keeping with Dr. Cranes previous research, MEDEA aims to compare the effect of a personalized telephone-based health education weight-loss program based on motivational coaching, exercise and diet, compared with a standard health educational program control on fatigue of overweight or obese breast cancer patients. Learn more.

According to new research from College of Nursing Associate Professor Ruth Taylor-Piliae, PhD, RN, FAHA, tai chi can be beneficial to the psychological well-being for adults suffering from cardiovascular disease. Published in June in the European Journal of Cardiovascular Nursing, Dr. Taylor-Piliaes review and meta-analysis of more than a dozen studies on the topic found that the exercise eased stress, anxiety, depression and psychological distress for those who practiced the mind-body exercise that emphasizes concentration on posture, relaxation and breathing, using a soothing series of set movements. Go to the UArizona Health Sciences Connect website for a video on her research. Learn more.

Three cardiologists recently joined the University of Arizona Sarver Heart Center. Arka Chatterjee, MD, Talal Moukabary, MD, and Madhan Sundaram, MBBS, joined the faculty of the UArizona College of Medicine Tucson and are now seeing patients at Banner University Medical Center Tucson.

With the addition of Drs. Chatterjee, Moukabary and Sundaram we continue the rapid growth in cardiovascular medicine at the University of Arizona and Banner UMC Tucson and we enhance our ability to provide highly personalized and expert care in the most advanced cardiology procedures to our patients, said Nancy K. Sweitzer, MD, PhD, director of the UArizona Sarver Heart Center, professor of medicine and chief of the Division of Cardiology in the Department of Medicine at the college.

These three physicians not only bring experience in electrophysiology, coronary and peripheral interventions and minimally invasive valve replacement, but they will expand the research offerings of the Sarver Heart Center in important areas of cardiology. This will allow us to bring the latest advances in heart disease treatment to the people of Southern Arizona, added Dr. Sweitzer.

Drs. Chatterjee and Moukabary are associate professors and Dr. Sundaram is an assistant professor of medicine.

In addition, Dr. Chatterjee is associate director of the Structural Heart Program at Banner UMC Tucson. He is board certified in interventional cardiology, cardiovascular disease, internal medicine and echocardiography. Dr. Chatterjee is experienced in transcatheter therapies for valvular disease and other congenital/structural heart defects. He has completed more than 200 transcatheter aortic valve replacement (TAVR) procedures. He finds the best part of working in the structural heart team is the synergy that occurs when a multidisciplinary team of expert providers works together to identify the ideal treatment for each patients unique case. Dr. Chatterjees research interests include outcomes research after coronary, structural and adult congenital interventions, and advances in structural and device therapies for heart disease.

Dr. Moukabary is a cardiac electrophysiologist (a cardiologist specializing in heart rhythm disorders or arrhythmias). He is an expert in computer modeling of cardiac arrhythmia, imaging in the cardiac electrophysiology lab, cell-based arrhythmia therapy and clinical cardiac electrophysiology. He is board certified in clinical cardiac electrophysiology and internal medicine. Dr. Moukabarys research interests include use of stem cell and iPS (induced pluripotent stem) cell therapies for heart rhythm disorders.

Dr. Sundaram is director of the Banner UMC Tucson Cardiac Catheterization Lab and Endovascular Services. He is board certified in interventional cardiology, cardiovascular disease, echocardiography and internal medicine. His clinical interests include complex coronary interventions, chronic total occlusions, endovascular peripheral interventions, interventions for acute pulmonary embolism and structural heart disease interventions. His research interests include cardiac interventions in older adults and clinical trials in coronary artery disease, peripheral artery disease and pulmonary embolism.

Read the rest here:
On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media

Recommendation and review posted by Bethany Smith

A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic conditions given its key advantages over CRISPR gene editing.

Since CRISPR-Cas9 gene editing was first reported in 2012, its promise of making gene editing faster, cheaper, and easier than ever before led to an explosion in the number of publications referring to this gene editing technology.

An increasing number of research labs and companies are aiming to translate CRISPR gene editing into therapies for genetic diseases. However, further research has unveiled that there are more limitations to using CRISPR-Cas9 to cure diseases than initially expected. For example, the technology has been reported to introduce off-target changes to the DNA, raising concerns about its safety.

In the meantime, RNA editing has emerged as an alternative to CRISPR technologies, getting a lot of attention from researchers and industry. RNA editing allows scientists to make changes in the molecules that carry the instructions needed to produce proteins, without changing the original DNA code.

One common method of RNA editing consists of using an enzyme called adenosine deaminase acting on RNA (ADAR), which uses a guide RNA sequence to identify the target RNA molecules and change one of its building blocks, or bases. This can be used to repair point mutations in the RNA instructions that would otherwise result in a damaged or even absent protein.

Although RNA editing was first described in the late 1980s, its therapeutic potential wasnt explored until 1995, when the US biotech Ribozyme Pharmaceuticals started researching it within the context of muscular dystrophy.

However, the concept of therapeutic RNA editing was quickly forgotten, only to be rediscovered nearly two decades later by German chemist Thorsten Stafforst from the University of Tbingen and the biologist Joshua Rosenthal of the Marine Biology Laboratory in Chicago, USA.

For Stafforst and Rosenthal, the timings of their respective publications on RNA editing in 2012 and 2013 were inconvenient. The news of CRISPR gene editing being possible in mammalian cells created such a buzz in the scientific community, that Stafforst himself experienced great difficulty in getting his results published. Who would need to edit RNA if we could already manipulate the DNA?

It took the FDA and EMA approval of the RNA interference drug patisiran in 2018 to revive the attention on the therapeutic potential of RNA editing. Since then, this technology seems to be experiencing momentum as it becomes increasingly clear that it might have some major advantages over CRISPR gene editing to treat human diseases.

First of all, ADAR is an enzyme naturally present in the human body. This means that for RNA editing therapies, only the guide RNA would need to be delivered. In contrast, CRISPR gene editing requires the delivery of the Cas9 protein in addition to an RNA guide. This protein is bulky and is obtained from microorganisms, which leaves it at risk of being recognized as foreign by the immune system.

An additional advantage is that guide RNAs belong to a class of drugs called antisense oligonucleotides, of which there are already six FDA-approved molecules available to treat a range of diseases. With the safety of guide RNA already established, the approval of RNA editing treatments could be significantly accelerated.

One of the strongest advantages of RNA editing is that changes to the RNA are only temporary. Concerns regarding irreversibly modifying human DNA would therefore cease with RNA editing. Even if off-target effects occur, they would disappear with time as the drug is eventually broken down and stops exerting its effects.

The biotech industry is increasingly recognizing the potential of RNA editing, with a growing number of companies and startups working in this field. Among them are ProQR, a Dutch company that focuses on treating rare genetic disorders that cause blindness; and Vico Therapeutics in Belgium, looking into spinocerebellar ataxia and Huntingtons disease.

Overseas, there is Edit Force in Japan, working in neurodegenerative conditions and cancer. In the US we find Shape Therapeutics and Locana; the latter develops treatments for motor-neuron disease and Huntingtons disease.

While these companies are raising big amounts of funding, their technology is still in the early stages. Some of them, like ProQR and Shape Therapeutics, have promising results in studies with mice, but none has tested the technology in humans yet. Although the process of RNA editing has been known since the 1980s, there are still some challenges to resolve before the technology can be taken to clinical trials.

Firstly, RNA is comparably unstable as a molecule and delicate to handle. Researchers are working on finding a delivery system that can direct the guide RNA to its target location while protecting it from degradation. Secondly, as with the RNA guides used for CRISPR gene editing, the RNA guides for RNA editing treatments can potentially cause an immune reaction, which needs to be ruled out individually before their approval.

Thirdly, RNA editing enzymes are very specific regarding which RNA bases they exchange. This means the technology is limited to a few kinds of changes, which, in turn, limits the number of conditions that it can treat, making it less attractive as a research tool when compared to CRISPR-Cas9. It will take some time until protein engineering allows us to modify RNA editing enzymes involved to expand the types of conversion they can perform.

Still, RNA editing seems to hold major promise to tackle diseases for which there is no cure available yet. Studies in mice showed results supporting RNA editing as a potentially powerful tool for genetic diseases like muscular dystrophy.

Before this technology becomes clinically viable, however, its efficiency will need to be optimized and its safety tested. At this point, it is not possible to say when, or if, RNA editing will make it to the clinic. But the latest research developments and the interest of the industry in RNA editing indicate that someday soon, these therapies might be able to help patients suffering from a wide range of diseases.

The author of this article wishes to remain anonymous

Images from Elena Resko and Shape Therapeutics

Read the original:
Overcoming the Limitations of CRISPR Gene Editing with RNA... - Labiotech.eu

Recommendation and review posted by Bethany Smith

With California Ag Today, Im Tim Hammerich.

UC Davis Animal Genomics Researcher Alison Van Eenennaam and her team have been working with CRISPR to try to improve cattle genetics.

Just as dairies ideally want heifer calves because they can ultimately produce milk, the beef industry wants bull calves, because they tend to be more feed efficient.

Van Eenennaam describes her teams genomic approach to solving this problem.

Van Eenenaam We did genome editing in the developing embryo of a bull and inserted a gene that's responsible for producing males. And this animal was born. His name is Cosmo. And we will know in his offspring, whether or not inheriting that particular gene results in the male appearance of animals that would otherwise be XX genotypic females. And so we haven't finished the experiment yet, but we have produced the gene-inserted genome-edited offspring, Cosmo.

Van Eenenaam says the birth of Cosmo is a big step in the project, but its not over yet.

Van Eenenaam So obviously half his offspring will be male because they'll inherit the Y chromosome, but the real ones we're interested in other ones that inherit the X chromosome, but also inherited the gene we inserted: SRY. Because our prediction is that we will actually have a male appearance in otherwise what would be XX genotypic females.

Read more from the original source:
CRISPR in Cattle - Part 2 - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Recommendation and review posted by Bethany Smith

Thesis

CRISPR Therapeutics (CRSP) is a high-risk, high-reward investment prospect. In my view, the market has mispriced the probability of CRISPR Therapeutics successfully utilizing the CRISPR/CAS9 platform across multiple disease states. In the most optimistic scenarios, the company could be worth several hundred billion dollars. The company is raising significant amounts of capital, which will allow it to invest across multiple disease states. I view this development extremely positively, as it comes on the heels of positive data from CTX001 and indicates the company is looking to solidify its lead in bringing CRISPR/CAS9 products to market. I am extremely bullish on the shares in the long run.

CRISPR Therapeutics was co-founded by Dr. Emmanuelle Charpentier together with Rodger Novak and Shaun Foy. In fact, Charpentier is generally credited with discovering how CRISPR/CAS9 could be applied for gene-editing purposes (along with colleague Jennifer Doudna). Currently, the company trying to apply the breakthrough gene-editing technology it's founder developed into the following disease states (per August 2020 Investor Presentation):

Hemoglobinopathies: This category includes various genetic diseases that affect the production of hemoglobin. Currently, the company has begun enrolling patients in Phase 1 trials for patients with beta-thalassemia and sickle cell disease. Both of these trials are in collaboration with Vertex Pharmaceutical (NASDAQ:VRTX) and will use the CTX001 treatment.

Immuno-oncology: This category includes drugs being developed to repurpose the human immune system in order to fight cancer. Currently, the company is developing three allogeneic CAR-T therapies for this purpose, which are enrolling patients now.

Regenerative Medicine: The company is currently researching a potential cure for Type 1 diabetes in partnership with Viacyte.

In vivo approaches: This category includes disease states, where gene-editing therapies could be applied. Currently, the company is researching cures for Glycogen Storage Disease, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1, and Cystic Fibrosis. Finally, the company has also noted it is working on additional undisclosed early-stage programs in partnership with Vertex and Bayer (OTCPK:BAYZF).

Source: August 2020 Investor Presentation

CRISPR Therapeutics pipeline appears both immature and aggressive. No therapy has progressed past a Phase 1 trial, and the company is already expanding into some of the most complex disease states. While this lack of specialization certainly presents execution risks, I believe the pipeline is well crafted. The company is expanding into diseases with larger patient population, which presents a more lucrative opportunity for therapy development. Furthermore, the company is diversifying how CRISPR/CAS9 technology will be utilized to create a therapy, as demonstrated by the difference between its CTX001 therapy, and its allogeneic CAR-T therapies.

Before moving onto the early data points, we have on efficacy, if you need a refresher on the technology, I highly recommend the ARK Invest White Paper on CRISPR. Their in-depth research coherently makes the case for why CRISPR is a superior gene-editing platform compared to existing approaches like ZFNs and TALENs.

The company currently has several data points back from its CTX001 ex vivo treatment, and the results are nothing short of stunning. For the two first Beta-Thalassemia patients treated, both are transfusion independent 5 months & 15 months after a CTX001 infusion. For reference, patient 1 averaged 34 units of packed red blood cell transfusions per year before the CTX001 infusion. Meanwhile, patient 2 required 61 units of packed red blood cell transfusions per year. For Sickle-Cell Disease, their first patient was experiencing seven vaso-occlusive crises and five packed red blood cell transfusions per year on average. After the CTX001 infusion, the patient has been vaso-occlusive crises free for nine months with zero red blood cell transfusions.

It is worth mentioning just how life-changing this therapy has already been for these patients. One beta-thalassemia patient was 19-year-old women with anemia, a low quality of life who needed multiple monthly transfusions. The disease was damaging her vital organs, and landing her trips into the hospital that was putting her life at risk. Since CTX001, these effects have subsided. The Sickle-Cell Disease patient, Victoria Gray, is a mother of three whose life was constantly put at risk from vaso-occlusive events. While scientists were initially hoping to increase her fetal hemoglobin to 20% of her total hemoglobin level, CTX001 increased that level to 46%. Additionally, a biopsy of her bone marrow cells showed that 81% of the cells contained the edited DNA, which would allow her body to maintain the higher fetal hemoglobin levels for a sustained period of time. Data aside, the patient's interview with NPR may summarize the results best, "It's wonderful. It's the change I've been waiting on my whole life".

Despite the success, there are concerns about the treatment that are yet to be addressed: 1) Is the treatment durable? The first Beta-thalassemia patient is transfusion independent after 15 months, but just how long will this effect last into the future? When the company begins to dose more patients, will they experience similar long-lasting results? The company will need to monitor its patients for a longer period of time to prove their therapies durability. 2) Is the treatment consistent? One of the chief concerns regarding gene editing is the accuracy and consistency with which companies can actually edit a patient's genome. Part of this concern is related to the actual technological process of the edit, and in that regard, CRISPR/CAS9 system is believed to be a consistent editor of DNA in cells. Additionally, a less publicized facet of the consistency concern stems from the ability to manufacture these complex treatments. In this regard, CRSIPR is one step ahead of the competition by launching a state-of-the-art manufacturing facility in Framingham, MA to support its programs.

I have been a long-time believer in gene-editing and the CRISPR platform, but I truly never anticipated CRISPR Therapeutics could release initial data this positive. I believe the company has an effective cure on its hands.

The company's Immuno-oncology ambitions rest heavily on the use of allogeneic CAR-T therapies. CRISPR Therapeutics believes that allogeneic therapies can be safely created and administered to patients, and offer greater treatment potential for patients as compared to autologous therapies. In short, autologous therapies use the patient's own cells, which are then edited and used for treatment, while allogeneic therapies use a single-source of cells that are not derived from the patient.

The companies first trial using its proprietary allogeneic CAR-T platform uses CTX110 for the treatment of CD19+ B-cell malignancies. Even though the trial is still enrolling patients, the company expects to report some top-line data for CT110 by the end of 2020. Although this readout will occur relatively soon, I think it will provide an important update on how mature the companies platform in immuno-oncology truly is. Unfortunately, due to the relatively complex nature of this disease and the treatment itself, I am not expecting the same type of blockbuster results we saw in Hemoglobinopathies, but I still expect a successful readout.

As it relates to CTX120 for the treatment of multiple myeloma and CTX130 for the treatment of solid tumors like renal cell carcinoma, the only data available is from testing on mice. However, it is worth noting that in both cases, all five mice treated with the appropriate infusion for their xenograft cancer were found to be completely cancer free. The graph below shows the observed progression for CTX120.

The company's main regenerative medicine therapy will be looking to treat Type 1 diabetes. The approach will utilize CRISPR/CAS9 to edit pluripotent stem cells for beta cell replacement, which will enable the new pancreatic cells to secrete insulin. The therapy will actually seek to leverage the technology it has developed for its allogeneic CAR-T platform in order to cure the disease. At this point, the company is still in the research stage with its partner Viacyte, so it will be quite a while before any substantial data comes from this work. Additionally, snuck into a recent press release, CRISPR announced that it is partnering with UHN, Canada's largest research hospital, in order to utilize gene-editing technology in order to turn stem cells into hepatocytes. This indicates that CRISPR is looking to extend its regenerative medicine franchise into liver diseases, which could potentially treat a large variety of patient populations

The therapies cited above are considered ex vivo treatments, as outside cells are edited and infused into the patient for treatment. In vivo therapies would directly edit the cells inside a person. This type of therapy presents higher risks and greater technological challenges for execution. Thus, as it relates to CRISPR's in vivo pipeline, I believe these therapies will need a significantly longer period of maturation until these products can successfully come to market. For the purposes of this analysis, I believe it is important to note that management is researching how to best bring these drugs to fruition, but CRISPR/CAS9 may not be the right technology to do that. Despite this risk, CEO Samarth Kulkarni has stated that he expects CRISPR Therapeutics to purchase and adapt to new technologies as they are developed, ensuring that the company will remain at the forefront of the gene-editing revolution.

CRISPR finished Q2 2020 on solid financial footing. Cash and Cash equivalents ended June 30, 2020 at $945M compared to $890M on March 30th, an increase of $55M. Financing provided $89M in cash, while a milestone payment from Vertex provided another $25M. Q2 2020 R&D expenses totaled $59M while G&A expenses were $21M, which combined for a net loss of $79.7M. With almost $1B of cash in the bank, enough to cover two years of operations, you may feel that CRISPR Therapeutics is a cash-rich company. Well, management would disagree, because on June 30th they announced another secondary share offering to raise ~$455M at $70 a share.

In my view, the capital raise is extremely prudent. Samarth expects gene-edited products to compose 30% of the global pharmaceutical market within 12 years, as stated at the William Blair Biotech Focus Conference. This implies a market opportunity of hundreds of billions of dollars, of which no company has become the global leader. This is a unique opportunity to become the market leader in pharmaceuticals and I believe CRISPR Therapeutics should raise and spend as much capital as necessary in order to capture this market. Secondly, management is once again raising capital at all-time high share prices, which I believe demonstrates a conservative management philosophy that will continue to serve shareholders well into the future.

CRISPR Therapeutics can be essentially considered a pre-revenue company, and will not have any commercial products for several years. However, for the sake of propriety, it is worth noting the potential market opportunity for a successful treatment. As noted in the company's 2019 annual report, there are estimated to be 200,000 people worldwide who are alive and registered as receiving treatment for Beta-Thalassemia, of which approximately 19,000 live in the US or Europe. Additionally, another 60,000 are born with the disease annually. For Sickle-Cell Disease, there are estimated to be 20-25 million people worldwide with the disease, of which 100,000 reside in the United States. Additionally, another 300,000 are born with the disease annually. Meanwhile, as Ark Invest noted in their white paper, the market for CAR-T therapies is expected to grow to over $100B annually. These market opportunities are exceptionally large, and this could allow CRISPR Therapeutics to generate billions of dollars annually from its lead therapies in Phase 1 trials today.

Meanwhile, from an operational standpoint, I believe CRISPR appears to be allocating its resources efficiently. Take a look at its operating expenses over the past five years. While General and Administrative costs were outpacing actual R&D when the company first started, management is now spending three times as much money on R&D as G&A. I am highly encouraged by this development, because as an investor, I want the capital being raised to be spent on value creation, not overhead. Finally, it is also worth noting that the company ended 2019 with just over 300 employees, but currently has 53 open positions. This indicates the company is hiring for massive growth, which will help it execute on its diverse array of disease programs.

CRISPR Therapeutics is my best high-risk, long-term investment idea. The initial CTX001 data has been incredible, the company is capitalizing on a surging share price, and investing heavily across multiple disease programs. CRISPR Therapeutics' current market cap is $6.3B, but any number of bullish scenario's involving multiple successful products could create a company valued in the hundreds of billions. This presents an opportunity with significant asymmetric upside for the share price if an investor is willing to take the risk.

It is also worth noting for the purposes of this article that there are several other similar companies operating in this segment of gene-editing technology, such as Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM). While CRISPR Therapeutics is generally regarded as the leader of this group, I am, in general, bullish on these other companies for two reasons: (1) I believe the bull case on CRISPR Therapeutics to be chiefly driven by the technological platform, which these other companies are also working to mature (2) I believe these shares will act as a hedge to single-stock risk, where the technological platform may succeed, but not necessarily with CRISPR's management or pipeline of products.

Source: August 2020 Investor Presentation

Disclosure: I am/we are long CRSP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I am long CRSP, EDIT, NTLA, and BEAM. I have been acquiring shares since 2017 in CRSP, and intend to continue gradually purchasing more shares. I am not an expert, and this is not financial advice.

Read the original post:
Crispr Therapeutics: My #1 High-Risk Investment Idea - Seeking Alpha

Recommendation and review posted by Bethany Smith

With California Ag Today, Im Tim Hammerich.

UC Davis Animal Genomics Researcher Alison Van Eenennaam has been working for five years to see if CRISPR can help us breed a line of cattle thats better tailored for the beef industrys needs.

Van Eenennaam CRISPR is a tool that can be used to introduce useful genetic variation into our cattle breeding programs. And it enables us to do targeted alterations to the genome and maybe inactivate genes that make cattle susceptible to disease, or give them the ability to be more heat tolerant. Traits that will better suit them to the environment and to have improved health.

Van Eenannaam and her team set out to see if one gene in particular could be introduced to help make the beef industry more efficient.

Van Eenannaam We're interested in seeing whether or not we could produce all male cattle for the beef industry where actually males in the feedlot sector would be the preferred sex. The same way dairy producers like female cattle to produce milk if possible, we'd like male cattle in the feedlot industry. There is a single gene called SRY that's responsible for the male developmental pathway, and we were interested in seeing whether, if we introduced that gene using CRISPR, whether we could actually produce all male offspring in the offspring of a bull.

Stay tuned for part 2 tomorrow where we introduce you to the first calf born with this gene.

More here:
CRISPR in Cattle - Part 1 - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Recommendation and review posted by Bethany Smith

A New Research Published byGMAon theGlobal CRISPR Technology Market (COVID 19 Version)in various regions to produce more than 200+ page reports. This study is a perfect blend of qualitative and quantifiable information highlighting key market developments, industry and competitors challenges in gap analysis and new opportunities and may be trending in theGlobal CRISPR Technology Market. Some are part of the coverage and are the core and emerging players being profiledThermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen.

Get Free Sample PDF Copy ofGlobal CRISPR Technology MarketReport @:grandmarketanalytics.com/Request-For-Sample-Report?/Global-CRISPR-Technology-Market-&id=72241

What we provide inGlobal CRISPR Technology MarketResearch Report?

Get Up to 40 % Discount on Enterprise Copy@grandmarketanalytics.com/Check-Discount-On-Report?/Global-CRISPR-Technology-Market-&id=72241

KEY BENEFITS

TheGlobal CRISPR Technology Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

TheGlobal CRISPR Technology Marketreport provides an in-depth review of industry dynamics inCRISPR Technology, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on theCRISPR Technologyreport.

Industry players strategic analysis and industry position in theGlobal CRISPR Technology Market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

Note: Please Share Your Budget on Call/Mail We will try to Reach your Requirement @Phone:+1 (925) 478-7203/Email:[emailprotected]

Make the Inquiry forGlobal CRISPR Technology MarketReport before Purchase @:grandmarketanalytics.com/Reports-Description-And-Details?/Global-CRISPR-Technology-Market-&id=72241

Quantitative data:

Breakdown of market data by main region & application / end-user

By typeEnzymes, Kits, gRNA, Libraries, Design Tools, ,

Global CRISPR Technology MarketReport-specific sales and growth rates for applicationsBiomedical, Agricultural, , (historical & forecast)

Global CRISPR Technology MarketProfits by sector and growth rate (history and forecast)

Global CRISPR Technology Marketsize and rate of growth, application and type (Past and Projected)

Global CRISPR Technology MarketSales income, volume and growth rate Y-O-Y (base year)

Qualitative data: Includes factors affecting or influencing market dynamics and market growth. To list some names in related sections

Industry overview

GlobalGlobal CRISPR Technology Marketgrowth driver

GlobalGlobal CRISPR Technology Markettrends

Incarceration

Global CRISPR Technology MarketOpportunity

Market entropy ** [specially designed to emphasize market aggressiveness]

Fungal analysis

Porter Five Army Model

Research Methodology:

Primary Research:

We interviewed various key sources of supply and demand in the course of thePrimary Researchto obtain qualitative and quantitative information related to this report. Main sources of supply include key industry members, subject matter experts from key companies, and consultants from many major firms and organizations working on theGlobal CRISPR Technology Market.

Secondary Research:

Secondary Researchwas performed to obtain crucial information about the business supply chain, the company currency system, global corporate pools, and sector segmentation, with the lowest point, regional area, and technology-oriented perspectives. Secondary data were collected and analyzed to reach the total size of the market which the first survey confirmed.

Customization Available for Following Regions & Country:North America, South & Central America, Middle East & Africa, Europe, Asia-Pacific

Buy Full Copy GlobalGlobal CRISPR Technology MarketReport 2020-2029 @grandmarketanalytics.com/payment/checkout?reportid=72241

The research provides answers to the following key questions:

1) Who are the key Top Key players in the GlobalGlobal CRISPR Technology Market Report?

Following are list of players:Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen.

Note: Regional Breakdown & Sectional purchase Available We provide Pie charts Best Customize Reports As per Requirements.

2) Which Are the Main Key Regions Cover in Reports?

Geographically, this report is divided into several main regions, consumption, revenue (million USD) andGlobal CRISPR Technology Marketshare and growth rate in these regions, from 2019 to 2029 (predicted), covering North America, Europe, Asia-Pacific, etc.

3) What is the projected market size & market growth rate for the 2019-2029 periodGlobal CRISPR Technology Marketindustry?

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so reach our business development executive @[emailprotected]

4) Can I include additional segmentation / market segmentation?

Yes. Additional granularity / market segmentation may be included depending on data availability and difficulty of survey. However, you should investigate and share detailed requirements before final confirmation to the customer.

5) What Is impact of COVID 19 on GlobalGlobal CRISPR Technology Market industry?

Before COVID 19Global CRISPR Technology MarketMarket Size Was XXX Million $ & After COVID 19 Excepted to Grow At a X% & XXX Million $.

TOC for GlobalGlobal CRISPR Technology MarketResearch Report is:

Section 1: Global Market ReviewGlobal CRISPR Technology Market(20132029)

Defining

Description

Classified

Applications

Facts

Chapter 2: Market Competition by Players/Suppliers 2013 and 2019

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2013-2019)

Sales

Revenue and market share

Chapter 4, 5 and 6: GlobalGlobal CRISPR Technology Marketby Type, Application & Players/Suppliers Profiles (2013-2019)

Continued..

Contact Us:GRAND MARKET ANALYTICSMark(Head of Business Development)Phone:+1 (925) 478-7203Email:[emailprotected]

Read the original here:
CRISPR Technology Market Demand & SWOT Analysis By 2029: Key Players Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies...

Recommendation and review posted by Bethany Smith

Gene Editing Service Market 2020

The Gene Editing Service survey report contains valuable insights into the industry. The Gene Editing Service report begins with an understanding of the current market scenario, and goes on to describe the products available in the market, along with their different applications. The report also discusses the manufacturing technology used for production processes and how the availability of the same can affect the market. Our Gene Editing Service survey report details the scope of growth of the industry and also looks into the different emerging trends in the market. Our report covers the forecast period 2020-2026. Our Gene Editing Service survey also provides a predicted market valuation for the forecast period, as well as a projected valuation by the end of the forecast period.

The report provides and in-depth analysis of the industrys tools, mechanisms, and sales and distribution methods, which significantly influence the scope for growth. With this information, the segmentation of the market is understood in a much clearer way. The global Gene Editing Service is influenced by a number of factors such as environmental fluctuations, socio-economic changes, new policies and regulations introduced by the government, and much more. The report also seeks to provide the reader with information regarding the key players in the Gene Editing Service, and how they have maintained their market shares.

The global Gene Editing Service survey report includes a section that details the segmentation of the industry and the different elements that influence growth. We provide a regional analysis to determine the key players based on geographical area. The report also includes important industry updates and news that can help the reader gather a more relevant understanding of the market, as well as its growth prospects.

The study encompasses profiles of major companies operating in the Capital Lease Market. Key players profiled in the report includes: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery, Genscript Biotech, GeneCopoeia, Integrated DNA Technologies, Eurofins Genomics, DNA 2.0 (ATUM), BBI Life Sciences, Genewiz, Gene Oracle, SBS Genetech, and Bio Basic

The final report will add the analysis of the Impact of Covid-19 in this report Gene Editing Service industry.

Get a Sample Copy Of Gene Editing Service Market @ https://www.reportsandmarkets.com/sample-request/global-gene-editing-service-market-research-by-type-end-use-and-region-covid-19-version?utm_source=thedailychronicle&utm_medium=36

Latest industry news

The global Gene Editing Service report survey includes the latest updates and news from the industry. The information provided will include the latest trends in the market, the release of new and innovative technology, arrival of new products, impact of governmental regulations on sales, and much more. The section will also include details of partnerships, acquisitions, mergers, and takeovers amongst the key players in the industry, and how this can alter the growth prospects.

Gene Editing Service Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Gene Editing Service Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Gene Editing Service market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Gene Editing Service market by identifying its various sub segments.

Focuses on the key global Gene Editing Service players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Gene Editing Service with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Gene Editing Service submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Gene Editing Service Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents: Gene Editing Service Market

Chapter 1: Overview of Gene Editing Service Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Inquiry Before [emailprotected] https://www.reportsandmarkets.com/sample-request/global-gene-editing-service-market-research-by-type-end-use-and-region-covid-19-version?utm_source=thedailychronicle&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the original post:
Gene Editing Service Market (Impact of COVID-19) Top Growing Companies: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo...

Recommendation and review posted by Bethany Smith

This intricately designed endeavor offered to highlight the primary developments in the Global CRISPR Technology Market are poised to equip report readers and research practitioners with high end technical nuances about the major growth inducing developments in the CRISPR Technology market that subsequently decide future prospects and key business discretion on the part of market players comprising both established as well as amateur ones aiming to strike timely disruption in the discussed CRISPR Technology market.

Request a sample of CRISPR Technology Market report @ https://www.orbisresearch.com/contacts/request-sample/4890422

In further discussions, the report continues to extend minute insightful cues to its readers market players, their growth objectives, long and short-term business goals and the like, based on which highly successful business ventures are mediated for maximum return on investments in global CRISPR Technology market.

The report reveals dynamic information about various knowledge factors such as sales volume and bulk production, pricing matrix and sales figures, overall growth review and margin, chances of growth in the future and their range amongst other additional growth determinants that influence growth in the CRISPR Technology market.

Key Manufacturers Analysis:

Thermo Fisher ScientificMerck KGaAGenScriptIntegrated DNA Technologies (IDT)Horizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

A thorough analytical documentation comprising market classification, supply chain nuances, best industry practices adhered by frontline players, minute methodical applications as well as a complete outlook of the competition spectrum have been minutely addressed in this section of the CRISPR Technology market report to influence a highly profitable market growth trajectory through the forecast span.

Access full report @ https://www.orbisresearch.com/reports/index/global-crispr-technology-market-report-2020

On the basis of the aforementioned market relevant information portrayed in the report, this illustrative research report also identifies the market segments that leverage high revenue growth in the CRISPR Technology market. The market identifies type and application as prominent growth steering factors that continue to remain prominent influencing growth the CRISPR Technology market.

CRISPR Technology market Segmentation by Type:

EnzymesKitsgRNALibrariesDesign Tools

CRISPR Technology market Segmentation by Application:

BiomedicalAgricultural

This section of the report is crucial in harnessing report readers understanding to decode, identify and pinpoint the segment in the CRISPR Technology market that inculcates revenue maximization without having any constraints that in due course hinder growth in global CRISPR Technology market.

An Analysis of the Geographical Span:

Besides a macroscopic analysis based on regional segmentation, the report also focuses on country-wise review of the CRISPR Technology market. This extensive research report compilation highlighting the details about market prognosis attempts to also unearth some of the concurrent developments and forces that strike growth in the global CRISPR Technology market.

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Reasons to Buy the Report:

1. The CRISPR Technology market report is a ready-to-go market specific document encompassing regional overview, opportunity mapping, and competition analysis.2. A critical review of dominant market trends, leading market strategies as well as best industry practices has also been tagged in the CRISPR Technology market report.3. The report is focusing specifically across a range of key development areas such as dynamic segmentation, cross sectional analysis of the target market.4. Access to extensive overview of the CRISPR Technology market at a multi-faceted perspective.5. Focus on real time market growth status to encourage accurate market specific decisions.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4890422

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Read more:
Global CRISPR Technology Market Trends, Industry Demand, Growth Analysis and 2025 Forecast Overview, Top Players Analysis- Thermo Fisher Scientific,...

Recommendation and review posted by Bethany Smith

New Jersey, United States,- The CRISPR and Cas Genes Market is predicted by Verified Market Researchs report to find players focusing on new product development to secure a strong position in terms of revenue sharing. Strategic collaboration can be a powerful way to bring new products to the market. The level of competition observed in the market may increase.

This research report categorizes the global market by players/brands, regions, types, and applications. The report also analyzes the global market status, competitive landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, five forces of distributors, and porters.

The latest 2020 edition of this report reserves the right to provide further comments on the latest scenarios, recession, and impact of COVID-19 on the entire industry. It also provides qualitative information on when the industry can rethink the goals the industry is taking to address the situation and possible actions.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

CRISPR and Cas Genes Market Segment Analysis-

The research report includes specific segments by Type and Application. Each type provides information about the production during the forecast period of 2015 to 2027. The application segment also provides consumption during the forecast period of 2015 to 2027. Understanding the segments helps in identifying the importance of different factors that aid market growth.

CRISPR and Cas Genes Market, By Product

Kits & Enzymes Libraries Design Tool Antibodies Others

CRISPR and Cas Genes Market, By Application

Biomedical Agricultural Other

CRISPR and Cas Genes Market, By End-User

Biotechnology & Pharmaceutical Companies Academic & Government Research Institutes Contract Research Organizations Others

The study analyses the following key business aspects:

Analysis of Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the CRISPR and Cas Genes market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the CRISPR and Cas Genes market.

Market Forecasts:Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the CRISPR and Cas Genes market.

Regional Growth Analysis:All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis:The report provides accurate and reliable forecasts of the market share of important segments of the CRISPR and Cas Genes market. Market participants can use this analysis to make strategic investments in key growth pockets of the CRISPR and Cas Genes market.

Business Opportunities in Following Regions and Countries:

North America (United States, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia, and Australia)

Latin America (Brazil, Argentina, and Colombia)

How will the report assist your business to grow?

The document offers statistical data about the value (US $) and size (units) for the CRISPR and Cas Genes industry between 2020 to 2027.

The report also traces the leading market rivals that will create and influence the CRISPR and Cas Genes business to a greater extent.

Extensive understanding of the fundamental trends impacting each sector, although greatest threat, latest technologies, and opportunities that could build the global CRISPR and Cas Genes market both supply and offer.

The report helps the customer to determine the substantial results of major market players or rulers of the CRISPR and Cas Genes sector.

Reason to Buy this Report:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global CRISPR and Cas Genes Market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in CRISPR and Cas Genes Market, thereby allowing players to develop effective long term strategies.

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Excerpt from:
CRISPR and Cas Genes Market Size By Product Analysis, By Application, By End-Users, By Regional Outlook, By Top Companies and Forecast to 2027 -...

Recommendation and review posted by Bethany Smith

While pre- and post-test education on genetic testing helped to educate patients, recent study findings may also highlight the way that telemedicine is revolutionizing the space, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

In an interview with CancerNetwork, Morgan, a genetic counselor at Memorial Sloan Kettering Cancer Center, explained how telemedicine is changing the future of genetic testing.

Transcription:

The current focus is going to be continuing to survey our participants and then analyze and report out our findings. These are sort of our first set of early results. But the goal from there is, there's a lot of different ways in which this information can probably be used in terms of next steps.

One of the things I mentioned was the idea of new ways to engage primary care providers. So that's certainly an area of interest. One thing I didn't mention, but it's also kind of along the lines of where we want to go is we were very happy with the recruitment that we achieved, but at the same time, we think this tool could be used even more broadly, potentially. So finding ways to better distribute this information and engage a broader number of participants. And then lastly, the immediate context for this is thinking about how this model may work for population screening in the Ashkenazi Jewish group. But there are ways that we could pivot this to other situations as well. So, whether that be things like testing family members for an unknown mutation, or maybe there are other groups with predominant risk factors where this model could work as well. So, I think that once we better understand the long term medical outcomes of participants, we will be able to continue to think about different ways that we can improve and change the model and then apply it further in this context and others as well.

I think, now more than ever, is a time where there's almost a digital revolution, if you will, and a lot of technology in the forefront. So, from our perspective, our goal is to find a way to leverage technology in the context of medicine and use it for better. So there's always a lot going on in terms of many different ways to access testing direct to consumer testing. And, you know, if and when this sort of convenience can be combined with medicine, I think there's a lot of opportunities for improved patient care through that partnership.

See original here:
Kelly Morgan, MS, CGC, the Future of Telemedicine and Genetic Testing - Cancer Network

Recommendation and review posted by Bethany Smith

Direct-to-Consumer (DTC) Genetic Testing Market Introduction

Direct-to-consumer (DTC) genetic testing refers to genetic testing that provides people with their genetic information wherein involvement of healthcare professional or Health Insurance Company is not necessary. While a number of companies are offering the direct-to-consumer (DTC) genetic testing, it is spreading awareness regarding genetic diseases that can be prevented in time. Direct-to-consumer (DTC) genetic testing also offers personalized information about overall health, potential disease risks and other genetic traits.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4770

The direct-to-consumer (DTC) genetic testing market is expected to witness significant growth in the future on the back of rising awareness among patients to go for early diagnosis and obtain in-time treatment. As the prevalence of genetic diseases and rare disorders is increasing across the globe, application of direct-to-consumer (DTC) genetic testing is expected to rise significantly in the coming years.

Direct-to-Consumer (DTC) Genetic Testing Market Notable Developments

Some of the most prominent competitors operating in the competitive landscape of global direct-to-consumer (DTC) genetic testing market include

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4770

Direct-to-Consumer (DTC) Genetic Testing Market Dynamics

Opportunities for Manufacturers as FDA Relieves Regulatory Hurdles

In June 2018, the U.S. FDA relieved some of the regulatory hurdles for manufacturers of the direct-to-consumer (DTC) genetic testing for health risk. As per the new regulatory updates, manufacturers, after receiving the first premarket approval for genetic health risk (GHR) test can commercialize the test without the requirement of additional review. GHR tests provide consumers with genetic risk information to consumers, however, it does not determine whether the person is at risk of developing a disease or a condition. While the regulatory process remains equally stringent, the FDA has warned against the use of multiple genetic tests with unapproved claims to predict patient response to a specific set of medications.

Prenatal and Newborn Direct-to-Consumer (DTC) Genetic Testing Demand On the Rise, Reliability Remains a Grey Area

Over the period of the last decade, individuals could easily purchase direct-to-consumer (DTC) genetic testing over online transactions to carry out prenatal and newborn genetic testing without the intervention of health professionals. However, companies that offer such tests lack a comprehensive standard data to which the testing results are compared. While the number of companies offering the direct-to-consumer (DTC) genetic testing for newborn screening is increasing, the reliability of their tests remains a grey area owing to the lack of supervision about test content, interpretation and accuracy.

Integration of Artificial Intelligence to Add Value in DTC Genetic Testing

Direct-to-consumer (DTC) genetic testing holds significant importance in the field of personalized medicine. Health data of an individual derived from direct-to-consumer (DTC) genetic testing in the form of genetic sequencing can be linked with other health indications to gain an overall health outlook. Towards this, many direct-to-consumer (DTC) genetic testing companies are engaged in collaborating with pharma companies. Also, with the integration of artificial intelligence (AI) in the medical diagnostic technologies such as direct-to-consumer (DTC) genetic testing, the derived genetic sequencing data becomes more valuable.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4770

Direct-to-Consumer (DTC) Genetic Testing Market Segmentation

Direct-to-consumer (DTC) genetic testing market is segmented on the basis of type, application and technology.

Based on type, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Based on application, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Based on technology, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Go here to see the original:
Direct-to-Consumer (DTC) Genetic Testing Market Analysis On Trends and Need 2028 - Scientect

Recommendation and review posted by Bethany Smith

Data Bridge Market Research has recently published the Global research Report TitledCardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Get Free Sample Report + All Related Graphs & Charts: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiovascular-genetic-testing-market

The Global Cardiovascular Genetic Testing Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Prominent Key Players Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Cardiovascular Genetic Testing market is presented in the research report. It is associated with the review of the downstream and upstream components of the Cardiovascular Genetic Testing Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Cardiovascular Genetic Testing market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiovascular-genetic-testing-market

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast to 2026

Reasons to Purchase this Report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Cardiovascular Genetic Testing Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cardiovascular-genetic-testing-market

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Link:
Cardiovascular Genetic Testing Market Estimated to Expand at a Robust CAGR over 2020 2027 - Scientect

Recommendation and review posted by Bethany Smith

Article In Brief

Scientists identified several cellular abnormalities in the developing cortex from fetal tissues carrying the mutant gene implicated in Huntington's disease. The findings suggest that the disease alters human development at an early age.

Teams of French researchers have found cellular changes that alter cortical development in the brains of human fetuses who carry the mutant huntingtin gene (mHTT) implicated in Huntington's disease (HD).

The finding adds a new wrinkle to the puzzle of HD as many people who carry the mutation can live healthy lives for four decades or longer before the onset of symptoms.

No one knows why, but this is a common thread in other late-onset genetically-driven neurodegenerative conditions like Alzheimer's and Parkinson's disease, the researchers said. And a growing number of researchers believe that it is best to treat people with the HD mutation as early as possible.Now, findings from this study, published online July 16 in Science, beg the question: How early?

The researchers, led by Sandrine Humbert, PhD, research director of INSERM (the French National Institute for Health and Medical Research) and group leader at the Grenoble Institut des Neurosciences, and Alexandra Durr, MD, PhD, professor at Sorbonne University and team leader of the Paris Brain Institute at Pitie-Salptrire Hospital, had access to fetal tissue from families that terminated their pregnancy in the context of a prenatal test. The developing fetus carried the mHTT.

Other mouse and neuroimaging studies with pre-manifest mutation carriers have suggested that the mutation might affect neurodevelopment but this is the first time that scientists have looked to the human fetus to know for sure.

Dr. Durr works with people undergoing genetic testing and counseling for Huntington's disease. Her team was able to collect cortical tissue from four HD mutation carriers when the pregnancies were terminated at around 13-weeks' gestation and tissue from four healthy controls.

This age is an opportune time to assess the tissue, the study authors noted, because at this stage the cortical neurons that project to the striatumthose that become dysfunctional and die during the course of the diseaseare being born from progenitor cells at the ventricular zone.

Thirteen weeks gestation is the time point when you need a lot of cells to be generated, Dr. Humbert explained. At this stage in development cells are massively cycling. The implications for the fetal brain with an HD mutation is that there is a shift to differentiate early and, as a result, you generate fewer neurons, at least at this specific time point during development.

The scientists identified several cellular abnormalities in the developing cortex, including mislocalization of the mutant huntingtin protein and other junction proteins that keep the neuroepithelium sealed. They observed abnormal ciliogenesis and changes in mitosis and cell-cycle progression, which correlated with defects in the balance between renewal and differentiation of progenitors.

In neuroprogenitor cells, this balance is tightly regulated to provide the right amount of neurons along the development of the cortex. Fewer proliferating cells and more progenitors prematurely began to differentiate in the tissues of HD carrierssubtle findings that are changing the landscape of the cortex.

Huntington's definitely has a neurodevelopmental component in addition to a neurodegenerative disease, Dr. Humbert explained. Studies in mice have found similar cellular abnormalities.

These data are supported by similar findings in mice that show mutant HTT impairs neuroprogenitor cell division, migration, and maturation, and that these changes result in a thinner cortex. Additional studies have revealed that early exposure to mutant HTT is enough to trigger signs of HD when the mice grow up. Neuroimaging studies with pre-symptomatic mutation carriers, even children, have shown smaller intracranial volume in HD mutation carriers.

What is also intriguing is that these events occurred even though the fetuses had small pathological expansions39, 40, and 42 repeats that would typically cause an adult onset of HD.

The findings trigger a number of questions: Why aren't there any obvious clinical problems until mid-life? Do these early developmental changes set the stage for symptoms decades down the road? Are other brain cells compensating for the changes and it takes 40-plus years for symptoms to develop?

Dr. Humbert and her colleagues said that the defects we observed likely render the cortico-striatal circuitry more vulnerable to the later dysfunctions characteristic of HD. The path to degeneration is complex, however, and weaves together both pathogenic and compensatory mechanisms.

They cited a recent pair of studies in Neurology by Peg Nopoulos, MD, and her colleagues at the University of Iowa, Carver College of Medicine that looked at children who are HD mutation carriers. They showed initial striatal enlargement with hyper-connectivity between the striatum and the cerebellum. Over time, the striatum decreases and the connections weaken. Although the cerebellar connections initially may help compensate for the abnormally developed striatum, it is the loss of these connections that may ultimately lead to motor abnormalities. Again, it will be decades before any obvious motor signs develop.

Once there are disease-modifying therapies, we know we should treat as early as possible or differently in pre-manifest compared to symptomatic stages of the disease, or it may not be sufficient, said Dr. Humbert.

She said she is now interested in understanding how these early defects contribute to adult pathology, and how their compensation could be regulated during the silent symptom-free period. This should give access to new molecules of interest, either as treatments or biomarkers, she added.

It is a beautiful paper, said Christopher A. Ross, MD, PhD, director of neurobiology and professor of psychiatry and behavioral sciences at Johns Hopkins Medicine. The concept fits with ideas people have had. Their study is groundbreaking.

It's unclear how these cell-cycle abnormalities alter normal development, said Dr. Ross. I have been doing pre-manifest genetic testing for years, and my belief is that asymptomatic people who are far from their predicted onset but test positive are clinically completely normal.

These data are very interesting, said Sarah Tabrizi, MD, PhD, professor of clinical neurology at University College London Institute of Neurology. There has been debate in the HD field regarding the existence of a neurodevelopmental deficit, and evidence is accruing that this may be the case based on differentiating HD induced pluripotent stem cell systems, mouse development, and now these studies of early human development.

We recently found that HD gene carriers ~24 years before predicted disease onset had essentially completely normal brains including normal cortico-striatal connectivity on advanced neuroimaging, apart from a slightly smaller striatum, which we hypothesized resulted in selective vulnerability of the striatum to subsequent neurodegeneration in HD (Lancet Neurology 2020). Importantly, our HD gene carriers performed as well as matched controls on a range of stringent cognitive and motor assessments.

This all suggests that we need to treat as early as possible with disease-modifying therapies to enable us to delay or prevent symptom onset, Dr. Tabrizi said, and means that there is still great potential for therapies to potentially prevent the neurodegeneration occurring if we treat early enough. We need to understand more about the very earliest manifestations of neurodegeneration and then intervene at the optimal stage.

Dr. Ross believes that the brain figures out a workaround of these developmental alterations but agrees that it may leave the brain more vulnerable later in life. He added, These findings are conceptually very important, though not necessarily with immediate implications for patients or those who are asymptomatic but test positive.

He said that this finding represents a paradigm shift that will lead scientists to look for developmental abnormalities in other neurodegenerative diseases.

It is important to emphasize how the Huntington gene (HTT) affects the brain in the context of a lifetime trajectory, added Dr. Nopoulos, the Paul W. Penningroth professor of psychiatry and chair in the department of psychiatry at University of Iowa Carver College of Medicine. This gene is vital for brain development. Our group has shown that HTT drives brain development and that repeats in HTT are beneficial, and the higher the repeat, the higher the IQ. For individuals with repeats in the range of 39-42, like those in the fetal tissue study, HTT likely contributed to the development of a cerebellar-striatal-cortical circuit that was initially advantageous (which is why they are found to be asymptomatic in the Tabrizi study), but later in life, vulnerable to degeneration. Therefore, although the findings in the fetal tissue study are reported as abnormalities, they are more likely to be evidence of differences since the changes are not pathologic until much later in life.

However, she added, everything about HTT is on a spectrumthe classic dose effect of repeats on the age of onset is a good example where greater repeats result in earlier onset. The same is likely true for development.

Human brain development is prolonged, lasting until roughly age 30, she continued. Those with repeats in the low mutant range (36-42) will have a chance for full brain development before the vulnerable cerebellar-striatal-cortical circuit begins to degenerate and disease manifests. However, in those with longer repeats (above 50), the vulnerable brain circuit may begin to degenerate before full brain maturation is complete.

In this range of repeats, the ultimate effect of mHTT on brain development may be detrimental. These considerations are vitally important when considering when to intervene with preventive therapies such as gene knock-down drugs. In those with low mutant repeats, knocking down the gene early in life (before age 30) may be detrimental to brain development, yet in those with high repeats, rescue may need to be much earlier (adolescence).

Drs. Humbert, Durr, Ross, and Nopoulos had no relevant disclosures.

Go here to read the rest:
Huntington's Disease Alters Human Development in the Fetal... : Neurology Today - LWW Journals

Recommendation and review posted by Bethany Smith